DAKTRONICS INC /SD/ Quarterly Accounts Receivable, after Allowance for Credit Loss, Current in USD from Q1 2011 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.
Summary
Daktronics Inc /Sd/ quarterly Accounts Receivable, after Allowance for Credit Loss, Current history and growth rate from Q1 2011 to Q3 2024.
  • Daktronics Inc /Sd/ Accounts Receivable, after Allowance for Credit Loss, Current for the quarter ending October 26, 2024 was $111M, a 3.26% decline year-over-year.
Accounts Receivable, after Allowance for Credit Loss, Current, Quarterly (USD)
Accounts Receivable, after Allowance for Credit Loss, Current, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q3 2024 $111M -$3.75M -3.26% Oct 26, 2024 10-Q 2024-12-04
Q2 2024 $132M +$6.41M +5.1% Jul 27, 2024 10-Q 2024-09-04
Q1 2024 $117M +$7.21M +6.55% Apr 27, 2024 10-Q 2024-12-04
Q4 2023 $101M -$15.2M -13.2% Jan 27, 2024 10-Q 2024-02-28
Q3 2023 $115M +$332K +0.29% Oct 28, 2023 10-Q 2023-12-05
Q2 2023 $126M +$12.4M +11% Jul 29, 2023 10-Q 2023-09-08
Q1 2023 $110M +$8.88M +8.78% Apr 29, 2023 10-K 2024-06-26
Q4 2022 $116M +$19.1M +19.8% Jan 28, 2023 10-Q 2023-03-13
Q3 2022 $115M +$19.6M +20.6% Oct 29, 2022 10-Q 2022-12-13
Q2 2022 $113M +$34.7M +44.2% Jul 30, 2022 10-Q 2022-09-02
Q1 2022 $101M +$33.3M +49.1% Apr 30, 2022 10-K 2023-07-12
Q4 2021 $96.7M +$33.5M +53% Jan 29, 2022 10-Q 2022-03-10
Q3 2021 $95.2M +$20.5M +27.4% Oct 30, 2021 10-Q 2021-12-01
Q2 2021 $78.5M -$10.1M -11.4% Jul 31, 2021 10-Q 2021-09-01
Q1 2021 $67.8M -$4.77M -6.57% May 1, 2021 10-K 2022-06-16
Q4 2020 $63.2M -$16.9M -21.1% Jan 30, 2021 10-Q 2021-03-03
Q3 2020 $74.7M -$28.7M -27.8% Oct 31, 2020 10-Q 2020-12-03
Q2 2020 $88.6M -$7.61M -7.91% Aug 1, 2020 10-Q 2020-08-28
Q1 2020 $72.6M +$7.09M +10.8% May 2, 2020 10-K 2021-06-11
Q4 2019 $80.1M +$2.4M +3.09% Feb 1, 2020 10-Q 2020-02-28
Q3 2019 $103M +$11.2M +12.2% Nov 2, 2019 10-Q 2019-11-27
Q2 2019 $96.2M -$4.14M -4.13% Aug 3, 2019 10-Q 2019-08-30
Q1 2019 $65.5M -$11.9M -15.4% Apr 27, 2019 10-K 2020-06-12
Q4 2018 $77.7M +$1.64M +2.15% Jan 26, 2019 10-Q 2019-02-22
Q3 2018 $92.2M -$16.5M -15.2% Oct 27, 2018 10-Q 2018-11-26
Q2 2018 $100M -$505K -0.5% Jul 28, 2018 10-Q 2018-08-24
Q1 2018 $77.4M -$1.46M -1.85% Apr 28, 2018 10-K 2019-06-07
Q4 2017 $76.1M +$4.47M +6.24% Jan 27, 2018 10-Q 2018-03-02
Q3 2017 $109M +$18.3M +20.2% Oct 28, 2017 10-Q 2017-12-01
Q2 2017 $101M +$14.5M +16.8% Jul 29, 2017 10-Q 2017-09-01
Q1 2017 $78.8M +$1.29M +1.67% Apr 29, 2017 10-K 2018-06-08
Q4 2016 $71.6M -$1.79M -2.44% Jan 28, 2017 10-Q 2017-03-03
Q3 2016 $90.4M -$517K -0.57% Oct 29, 2016 10-Q 2016-12-02
Q2 2016 $86.4M +$3.63M +4.38% Jul 30, 2016 10-Q 2016-09-02
Q1 2016 $77.6M -$3.3M -4.09% Apr 30, 2016 10-K 2017-06-09
Q4 2015 $73.4M -$5.07M -6.45% Jan 30, 2016 10-Q 2016-03-04
Q3 2015 $90.9M -$4.32M -4.54% Oct 31, 2015 10-Q 2015-12-04
Q2 2015 $82.8M -$3.76M -4.34% Aug 1, 2015 10-Q 2015-09-03
Q1 2015 $80.9M -$1.64M -1.99% May 2, 2015 10-K 2016-06-21
Q4 2014 $78.5M +$12.2M +18.4% Jan 31, 2015 10-Q 2015-03-06
Q3 2014 $95.3M +$28.3M +42.4% Nov 1, 2014 10-Q 2014-12-05
Q2 2014 $86.5M -$410K -0.47% Aug 2, 2014 10-Q 2014-09-05
Q1 2014 $82.5M +$19.3M +30.5% Apr 26, 2014 10-K 2015-06-22
Q4 2013 $66.3M +$6.73M +11.3% Jan 25, 2014 10-Q 2014-02-28
Q3 2013 $66.9M -$4.28M -6.01% Oct 26, 2013 10-Q 2013-11-27
Q2 2013 $86.9M +$10.2M +13.4% Jul 27, 2013 10-Q 2013-08-30
Q1 2013 $63.2M -$3.7M -5.52% Apr 27, 2013 10-K 2014-06-12
Q4 2012 $59.6M +$5.67M +10.5% Jan 26, 2013 10-Q 2013-03-01
Q3 2012 $71.2M +$12.7M +21.8% Oct 27, 2012 10-Q 2012-11-30
Q2 2012 $76.7M +$21.4M +38.7% Jul 28, 2012 10-Q 2012-08-31
Q1 2012 $66.9M +$5.15M +8.33% Apr 28, 2012 10-K 2013-06-12
Q4 2011 $53.9M Jan 28, 2012 10-Q 2012-03-02
Q3 2011 $58.5M Oct 29, 2011 10-Q 2011-12-02
Q2 2011 $55.3M Jul 30, 2011 10-Q 2011-09-02
Q1 2011 $61.8M Apr 30, 2011 10-K 2012-06-13
* An asterisk sign (*) next to the value indicates that the value is likely invalid.